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Background. The incidence of bacterial sepsis during the neonatal period is high. Mannan-binding lectin
(MBL), L-ficolin, and H-ficolin recognize microorganisms and activate the complement system via MBL-associated
serine proteases (MASPs). This study investigated whether cord blood concentrations of the lectin pathway proteins
are associated with neonatal sepsis.
Methods. This was a case-control study including 47 infants with culture-proven sepsis during the first month
of life and 94 matched controls. MBL, L-ficolin, H-ficolin, MASP-2, and MASP-3 levels were measured in cord
blood with use of enzyme-linked immunosorbent assay and time-resolved immunofluorometric assay. Multivariate
logistic regression was performed.
Results. Infants with gram-positive sepsis had significantly lower H-ficolin cord blood concentrations than
controls (multivariate odds ratio [OR], 4.00; 95% confidence interval [CI], 1.51–10.56; ), whereas infantsPp .005
with gram-negative sepsis had lower MBL cord blood concentrations (OR, 2.99; 95% CI, 0.86–10.33; ).Pp .084
When excluding patients with postoperative sepsis, multivariate analysis confirmed that low H-ficolin was associated
with a significantly higher risk of gram-positive sepsis (OR, 3.71; 95% CI, 1.26–10.92; ) and late-onsetPp .017
sepsis (OR, 3.14; 95% CI, 1.07–9.21; ). In contrast, low MBL was associated with a significantly higherPp .037
risk of gram-negative sepsis (OR, 4.39; 95% CI, 1.10–17.45; ) and early-onset sepsis (OR, 3.87; 95% CI,Pp .036
1.05–14.29; ). The concentrations of all the lectin pathway proteins increased with gestational age (Pp .042 P !
)..01
Conclusions. These preliminary results indicate that low MBL concentrations are a susceptibility factor for
gram-negative sepsis, and low H-ficolin concentrations indicate susceptibility to gram-positive sepsis. The decreased
expression of lectin pathway proteins in neonates must be considered to be an additional form of neonatal
immunodeficiency.
Severe infections represent the main cause of neonatal
mortality accounting for 11 million neonatal deaths
worldwide every year [1]. Thanks to advances in per-
inatal and intensive care, the prognosis for infants has
improved over the last decade [2]. Implementation of
recommendations for antibiotic prophylaxis in mothers
carrying group B streptococci (GBS) has lead to a sig-
nificant decrease in GBS neonatal sepsis [3]. However,
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even in developed countries, morbidity and mortality
due to neonatal sepsis remain high and cause severe
long-term sequelae, such as bronchopulmonary dys-
plasia and cerebral paresis [4, 5].
The adaptive immune system of neonates, particu-
larly of preterm infants, is severely impaired because of
immature B and T cell function [6, 7]. After birth, the
neonate is exposed to a diversity of potentially lethal
pathogens never confronted by its immune system. In
the absence of a functional adaptive immunity, pro-
tection by innate immune defenses is crucial [8]. Innate
immunity is mediated by pattern recognition molecules
recognizing conserved pathogen-associated molecular
patterns, such as repetitive sugar arrays present on
many microorganisms but not on mammalian cells [9].
The complement system, a mainstay of innate immuni-
154 • CID 2010:51 (15 July) • Schlapbach et al
ty, eliminates microorganisms and enhances adaptive immune
response [9]. Complement activation occurs by the classical,
the alternative, and the evolutionary more ancient lectin path-
way [10, 11]. The latter consists of soluble pattern recognition
molecules containing collagen-like regions, namely mannan-
binding lectin (MBL), L-ficolin (ficolin-2), and H-ficolin (fi-
colin-3 or Hakata-antigen) [12]. Both MBL and ficolins rely
on MBL-associated serine proteases (MASPs) to activate the
complement system [9]. On binding of MBL-MASP or ficolin-
MASP complexes to microbial surfaces, MASP-2 sequentially
cleaves C4 and C2, thereby generating the C3 convertase
C4bC2b, which leads to opsonization and lysis of pathogens
and recruitment of inflammatory cells [13].
MBL recognizes a broad range of pathogens exposing sugar
residues, whereas ficolins bind to acetylated molecules on mi-
crobial surfaces, such as GlcNAc and GalNAc [9, 14, 15]. Be-
cause of single nucleotide polymorphisms within the MBL2
gene and the associated promoter region, MBL deficiency af-
fects ∼30% of the white population [9]. Single nucleotide poly-
morphisms resulting in decreased protein concentrations have
been identified in the genes encoding ficolins (FCN1, FCN2,
and FCN3) and MASPs (MASP1 and MASP2) [16, 17].
MBL deficiency has been extensively investigated in adult
patients and is associated with an increased susceptibility to
sepsis [18–21]. In contrast, studies on neonatal sepsis yielded
partially conflicting results [22–26]. In spite of the close struc-
tural and functional similarities, the role of ficolins and MASPs
in sepsis remains largely unknown [9], and no study has as-
sessed the role of the entire lectin pathway of complement in
host immunity. The aim of the present study was to investigate
whether cord blood concentrations of lectin pathway proteins
are associated with neonatal sepsis.
PATIENTS AND METHODS
Patients. Infants born from November 2002 through Novem-
ber 2007 at the Department of Obstetrics, University of Bern,
Switzerland, were eligible for this study if cord blood serum
had been retrieved and stored. Sepsis cases were defined as infants
fulfilling all of the following criteria: (1) clinical signs of sepsis
(temperature instability, irritability, apathia, feeding difficulties,
prolonged capillary refill, apnea, tachycardia, or tachypnea); (2)
elevated infectious parameters (C-reactive protein level, 120 mg/
L; leukocyte level, ! leukocytes/L, immature/total neu-95 10
trophil ratio, 10.2); (3) recovery of pathogens in blood-culture
within the first 30 days of life; and (4) treatment for at least 7
days with intravenous antibiotics. Blood cultures yielding either
coagulase-negative staphylococci or Staphylococcus aureus were
considered to be contaminants if the infant was not fulfilling all
the above-mentioned criteria, or if the attending physician had
considered the bacterium as a contaminant. The study was ap-
proved by the institutional review board.
Controls and matching criteria. For each patient, 2 con-
trols who did not have infections during the neonatal period
were matched for the following criteria: (1) gestational age (1
week); (2) sex; and (3) chorioamnionitis, defined as maternal
fever, elevated maternal C-reactive protein level, fetal tachy-
cardia, prolonged rupture of membranes, and/or placental his-
tology indicative of chorioamnionitis [27]. Infants were not
eligible to be controls if they had developed proven or probable
neonatal infection or if they had received antibiotic treatment
for suspected neonatal infection for 172 h.
Measurements of proteins of the lectin pathway. Cord
blood is routinely collected and stored at our institution to
determine Toxoplasma gondii serology. After coagulation and
centrifugation, cord blood serum was frozen in sterile tubes at
80C. MBL, MASP-2, and L-ficolin concentrations were mea-
sured using commercially available enzyme-linked immuno-
sorbent assays, according to manufacturers’ instructions (MBL
oligomer ELISA kit, Antibodyshop; MASP-2 HK326 ELISA kit
and L-ficolin HK 336 ELISA kit, HyCult Biotechnology).
The concentrations of H-ficolin were measured by time-re-
solved immunofluorometric assay, as described elsewhere [28].
In brief, microtiter plates were coated with monoclonal anti–
H-ficolin antibody (4H5; HyCult Biotechnology), and serum
samples diluted 1000-fold were added to the wells. After in-
cubation and wash, the wells were incubated with biotinylated
monoclonal anti–H-ficolin antibody and were finally developed
by incubation with europium-labeled streptavidin followed by
measurement of the bound europium by time-resolved fluo-
rometry. Normal human standard serum with known content
of H-ficolin was used to construct the standard curve. In the
assay, we included 3 different control sera for test of interassay
reproducibility (coefficients of variation, 9.6% for 9800 ng/mL,
8.2% for 16,800 ng/mL, and 11.8% for 24,100 ng/mL).
For quantification of MASP-3, microtiter wells were coated
with 0.2 mg anti-MASP-1/3 antibody (MAb 1E2, subclass IgG1,
Hycult Biotechnology, reacting with an epitope within the N-
terminal domains shared by MASP-1 and MASP-3) in phos-
phate-buffered saline [29]. The wells were blocked with human
serum albumin (1 mg/mL 0.14 mol/L NaCl, 10 mmol/L Tris,
15 mmol/L NaN3, pH 7.4; TBS) and washed; next, samples
were added, diluted 50-fold in MASP-3 binding buffer (1 mol/
L NaCl, 10 mmol/L Tris-HCl, 5 mmol/L CaCl2, 15 mmol/L
NaN3, pH 7.4, 0.05% [v/v] Triton X-100, 100 mg heat aggregated
human IgG/mL [added to block the signals caused by rheu-
matoid factor if present in the samples]). A standard plasma
pool with 5330 ng/mL of MASP-3 (estimated by comparison
with dilutions of purified rMASP-3) was used to construct the
standard curve. The standard plasma was diluted 1:10 followed
by 2.5-fold dilutions (8 times). Following incubation overnight,
the wells were washed with TBS (5 mmol/L CaCl2, 0.05% Tween
20; TBS/Tw/Ca]) and were incubated with 1 mg of biotinylated
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(n p 94) P a
Male sexb 20 (43) 40 (43) 1.99
Gestational age,b median weeks (IQR) 31 (28–34) 32 (29–35) .46
Birth weight, median g (IQR) 1500 (1095–2430) 1645 (1119–2193) .79
SGA 8 (17) 18 (19) .76
Prenatal steroids 34 (72) 72 (77) .58
Maternal chorioamnionitisb 19 (40) 38 (40) 1.99
Maternal fever 3 (6) 2 (2) .22
PROM 8 (17) 24 (26) .26
Elevated maternal CRP 13 (28) 24 (26) .79
Cesarean section 33 (70) 60 (64) .45
Apgar 1 min, median score (IQR) 6 (3–7) 6 (5–8) .06
Apgar 5 min, median score (IQR) 8 (7–9) 8 (7–9) .32
Apgar 10 min, median score (IQR) 9 (8–9) 9 (8–9) .49
Umbilical artery pH, median pH (IQR) 7.29 (7.23–7.33) 7.29 (7.25–7.34) .09
Mechanical ventilationc 19 (40) 29 (31) .26
NOTE. Data are no (%) of persons, unless otherwise indicated. CRP, C-reactive protein; IQR, interquartile
range; PROM, prolonged rupture of membranes (118 h); SGA, small for gestational age (birth weight !10th
percentile for gestational age).
a P value determined by univariate logistic regression.
b Matching criteria.
c Intubation for respiratory distress syndrome before onset of sepsis.
anti–MASP-3 antibody (MAb 38:12–3) in 100 mL of TBS/Tw/
Ca containing 1% (v/v) bovine serum. The wells were washed,
incubated with europium-labelled streptavidin, and measured
as described above. Three internal controls were added to each
assay plate. The means and interassay coefficient of variations,
determined from 15 individual assays, were 7%, 6%, and 8%
for the 3 internal controls of 510 ng/mL, 2280 ng/mL, and 4950
ng/mL, respectively. The sensitivity for MASP-3 of the assay
(ie, the concentration yielding a signal 2 standard deviations
above the background) was 1000 ng/mL.
Statistical analysis. Outcomes were occurrence of sepsis,
gram-positive and gram-negative sepsis, and early-onset sepsis
(EOS, !72 h of life) versus late-onset sepsis (LOS, 172 h of
life). Because no data are available for normal values of lectin
pathway proteins in neonates, we used receiver operating char-
acteristic curve analysis with sepsis as outcome to define cut-
offs for low concentrations, resulting in the following catego-
rizations: (1) low MBL !300 ng/mL versus normal MBL 300
ng/mL, (2) low H-ficolin !12,000 ng/mL versus normal H-
ficolin 12,000 ng/mL, (3) low L-ficolin !1000 ng/mL versus
normal L-ficolin 1000 ng/mL, (4) low MASP-2 !30 ng/mL
versus normal MASP-2 30 ng/mL, and (5) low MASP-3
!3000 ng/mL versus normal MASP-3 3000 ng/mL.
Patients and controls were compared using univariate and
multivariate logistic regression with sepsis or type of sepsis as
the dependent variable. The concentration of lectin pathway
proteins, gestational age, chorioamnionitis, mode of delivery,
and mechanical ventilation after birth were included as covar-
iates. Spearman’s rank correlation was used to assess correlation
between gestational age or birth weight and lectin pathway
parameters. Two-sided tests were used throughout, and P val-
ues !.05 were considered to be significant. SPSS, version 18.0
(SPSS) software was used for all analyses.
RESULTS
During the study period, 72 infants for whom cord blood serum
was available developed blood culture–positive sepsis within
the first 30 days of life. Twenty-four (33%) cases were consid-
ered to be due to contaminants. One infant who died of me-
ningococcal sepsis was excluded because cord blood was not
available in sufficient quantities. Thus, 47 infants with a median
gestational age of 31 weeks (range, 24–41 weeks) were enrolled
as patients in the study. Baseline characteristics between the
case patients with sepsis ( ) and the matched controlsnp 47
( ) did not differ significantly (Table 1). Infants devel-np 94
oped sepsis at a median age of 7 days (range, 0–27 days) with
13 (28%) classified as EOS and 34 (72%) as LOS (Table 2). Six
infants (13%) required treatment with catecholamines because
of septic shock, and 5 infants (10%) died during sepsis. Max-
imum C-reactive protein levels during sepsis was at median 62
mg/L (range, 21–246 mg/L). Thirty-one episodes (66%) were
due to gram-positive and 15 (32%) to gram-negative organ-
isms; 1 episode (2%) was due to fungal infection. Eleven (23%)
infants developed sepsis after surgery for congenital malfor-
mation or necrotizing enterocolitis (Table 2).
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no (%)EOS LOS Surgerya
Gram positive
Staphylococcus aureus 1 15 4 16 (34)
Coagulase-negative staphylococci 0 10 4 10 (21)
Group B streptococci 2 1 0 3 (6)
Streptococcus viridans 1 0 0 1 (2)
Listeria monocytogenes 1 0 0 1 (2)
All gram-positive bacteria 5 26 8 31 (66)
Gram negative
Escherichia coli 6 3 0 9 (19)
Enterobacter cloacae 0 3 2 3 (6)
Haemophilus influenzae 1 0 0 1 (2)
Proteus mirabilis 1 0 0 1 (2)
Acinetobacter baumanii 0 1 1 1 (2)
All gram-negative bacteria 8 7 3 15 (32)
Fungal
Candida albicans 0 1 0 1 (2)
All fungal septicemias 0 1 0 1 (2)
Total, no (%) of isolates 13 (28) 34 (72) 11 (23) 47 (100)
NOTE. Data are no of isolates, unless otherwise indicated. EOS, early-onset sepsis (!72 h after birth);
LOS, late-onset sepsis (172 h after birth).
a Surgery indicates infants with postoperative sepsis (all LOS).
When analyzing cord blood concentrations of the lectin path-
way proteins in the whole study population (patients and con-
trols, ), median concentrations were as follows: MBL,np 141
1439 ng/mL (range, undetectable to 7166 ng/mL), H-ficolin,
12,573 ng/mL (range, 4434–34,655 ng/mL), L-ficolin, 2251 ng/
mL (range, 313–16,836 ng/mL), MASP-2, 55 ng/mL (range,
undetectable to 494 ng/mL), and MASP-3, 3233 ng/mL (range,
724–8569 ng/mL). Forty eight infants (34%) had MASP-2 con-
centration below the detection limit of 12.5 ng/mL. MBL, H-
ficolin, L-ficolin, MASP-2, and MASP-3 concentrations were
correlated with gestational age ( for all, by Spearman’sP ! .01
rank test; Figure 1) and birth weight ( for all).P ! .01
When comparing sepsis case patients and controls, H-ficolin
concentrations in cord blood were significantly lower in infants
with sepsis (odds ratio [OR], 2.17; ), whereas no dif-Pp .032
ference was found for the other lectin pathway proteins (Figure
2). Twenty (65%) of 31 infants with gram-positive sepsis and
21 (62%) of 34 infants with LOS, compared with 36 (38%) of
94 controls, had low H-ficolin levels, defined as !12,000 ng/
mL ( for both; Figure 3 and Table 3). In a multivariateP ! .05
analysis adjusted for gestational age, chorioamnionitis, mode of
delivery, and mechanical ventilation, low H-ficolin cord blood
concentration was associated with a significantly increased OR
of 4.00 for gram-positive sepsis (95% confidence interval [CI],
1.51–10.56; ) and an OR of 2.97 for LOS (95% CI,Pp .005
1.21–7.31; ).Pp .018
Six (40%) of 15 infants with gram-negative sepsis and 6
(46%) of 13 infants with EOS, compared to 17 (18%) of 94
controls had low MBL levels, defined as !300 ng/mL (Pp
for gram-negative sepsis and for EOS; Figure 4.062 Pp .028
and Table 3). In multivariate analysis, low MBL level was as-
sociated with an OR of 2.99 for gram-negative sepsis (95% CI,
0.86–10.33; ) and an OR of 3.87 for EOS (95% CI,Pp .084
1.05–14.29; ).Pp .042
Because infants with postoperative sepsis are exposed to par-
ticular risk factors, we then excluded all infants who had un-
dergone surgery during the first month of life ( ), leavingnp 11
36 case patients and 94 controls. In univariate and multivariate
analyses, low H-ficolin cord blood concentration was associated
with a significantly increased risk of gram-positive sepsis (mul-
tivariate OR, 3.71; 95% CI, 1.26–10.92; ; Table 4) andPp .017
LOS (OR, 3.14; 95% CI, 1.07–9.21; ), confirming thePp .037
main results. Again, low MBL cord blood concentration was
associated with a significantly increased risk of gram-negative
sepsis (OR, 4.39; 95% CI, 1.10–17.45; ) and EOS (OR,Pp .036
3.87; 95% CI, 1.05–14.29; ).Pp .042
DISCUSSION
The results of this preliminary study indicate differential roles
of lectin pathway proteins in susceptibility to neonatal sepsis.
Low H-ficolin cord blood concentration was associated with
significantly increased risk of gram-positive sepsis and LOS. In
contrast, low MBL was associated an increased risk of gram-
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Figure 1. Concentrations of mannan-binding lectin (MBL), H-ficolin, L-ficolin, MBL-associated serine protease (MASP)-2, and MASP-3 in cord blood and
gestational age in the whole cohort (patients and controls). The regression line is shown (dotted line). P values and correlation coefficients determined by
Spearman’s rank test are shown.
negative sepsis and EOS. In addition, we show that the ex-
pression of the lectin pathway of complement activation is very
immature in neonates.
Overall the concentrations of the lectin pathway proteins mea-
sured in this cohort were lower, compared with children and
adults, and were strongly correlated with gestational age [28, 30–
34]. We have previously shown that MASP-2, L-ficolin, and H-
ficolin concentrations increase over the first 6 months of life [31,
32], when they reach adult levels. These findings indicate that
the lectin pathway of complement activation is not fully func-
tional at birth. Decreased expression of lectin pathway proteins
during the neonatal period, in particular, in premature infants,
may thus contribute to the extraordinary susceptibility of new-
borns to invasive infections. This must be considered to be an
additional form of neonatal immunodeficiency.
Infants with low H-ficolin cord blood concentration had a
significantly increased risk to develop gram-positive sepsis,
compared with infants with normal H-ficolin levels. Multivar-
iate analysis adjusted for several potential confounders con-
firmed that low H-ficolin level was associated with a 4-fold
increased risk of gram-positive sepsis. Because most gram-pos-
itive infections occurred after day 3 of life, LOS occurred sig-
nificantly more often in infants with low H-ficolin levels. It is
thus highly unlikely that consumption of H-ficolin in the course
of chorioamnionitis influenced this association. Importantly,
when patients with postoperative sepsis were excluded, the as-
sociation between low H-ficolin and gram-positive sepsis re-
mained essentially unchanged, indicating the robustness of
this finding.
To date, the role of H-ficolin in health and disease re-
mains largely unknown. In contrast to other lectin pathway
members, H-ficolin is present only in humans, and severe H-
ficolin deficiency is extremely rare [9], suggesting an important
role for H-ficolin in human immune defense. Clinical studies
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Figure 2. Comparison of mannan-binding lectin (MBL), H-ficolin, L-ficolin, MBL-associated serine protease (MASP)-2, and MASP-3 concentrations in cord
blood between patients ( ) and controls ( ). P values determined by univariate logistic regression (if ) and median values are shown.np 47 np 94 P ! .05
The dotted lines indicate low concentrations.
Figure 3. H-ficolin concentrations in cord blood of patients with gram-
positive and gram-negative sepsis, compared with controls. P values de-
termined by univariate logistic regression and median values are shown.
The dotted line indicates low H-ficolin concentration (!12,000 ng/mL).
on H-ficolin are scarce. In a recent study including oncologic
children, patients with low H-ficolin levels experienced che-
motherapy-related infections and bacteremia significantly more
often [28]. Only recently, a case of H-ficolin deficiency was
reported in a 32-year-old man who had experienced repeated
respiratory tract infections since early childhood and brain ab-
scess due to gram-positive bacteria [35].
The bacterial specificity of H-ficolin remains to be deter-
mined [9]. H-ficolin recognizes acetylated surface structures
such as GlcNAc and GalNAc, which are exposed by many gram-
positive bacteria, but it also reacts with other acetylated com-
pounds [14]. Strong H-ficolin binding has thus far only been
demonstrated for Aerococcus viridans [14, 36]. Although bind-
ing of L-ficolin to lipoteichoic acid, a cell wall component of
gram-positive bacteria, particularly GBS, has been demon-
strated [14, 37], L-ficolin was not associated with particular
pathogens in the present study, which had a very low incidence
of GBS sepsis.
Infants with low MBL cord blood concentration had an in-
creased risk of developing gram-negative sepsis and EOS, com-
pared with infants with normal MBL levels. In multivariate anal-
ysis, low MBL concentration was associated with a 3- to 4-fold
increased risk of gram-negative sepsis. Importantly, when ex-
cluding patients with postoperative sepsis, low MBL concentra-
tion was even stronger associated with gram-negative sepsis. In-
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Table 3. Associations of Mannan-Binding Lectin (MBL), H-Ficolin, L-Ficolin, MBL-Associated Serine Protease (MASP)-








(n p 94) OR (95% CI) P OR (95% CI) P
Sepsis (n p 47)
MBL !300 ng/mL 11 (23) 17 (18) 1.38 (0.59–3.26) .457 1.45 (0.60–3.51) .404
H-ficolin !12,000 ng/mL 27 (57) 36 (38) 2.17 (1.07–4.43) .032c 2.12 (0.99–4.55) .053
L-ficolin !1000 ng/mL 15 (32) 22 (23) 1.53 (0.71–3.34) .281 1.33 (0.56–3.18) .516
MASP-2 !30 ng/mL 16 (34) 39 (41) 1.37 (0.66–2.85) .394 0.68 (0.32–1.44) .311
MASP-3 !3000 ng/mL 24 (51) 34 (36) 1.84 (0.91–3.75) .092 2.03 (0.88–4.71) .098
Gram-positive sepsis (n p 31)
MBL !300 ng/mL 4 (13) 17 (18) 0.67 (0.21–2.17) .505 0.82 (0.24–2.74) .745
H-ficolin !12,000 ng/mL 20 (65) 36 (38) 2.93 (1.26–6.82) .013c 4.00 (1.51–10.56) .005d
L-ficolin !1000 ng/mL 8 (26) 22 (23) 1.14 (0.45–2.90) .786 1.14 (0.45–2.90) .786
MASP-2 !30 ng/mL 11 (35) 39 (41) 0.78 (0.33–1.80) .554 0.78 (0.32–1.87) .572
MASP-3 !3000 ng/mL 15 (48) 34 (36) 1.65 (0.73–3.76) .229 2.39 (0.87–6.57) .091
Gram-negative sepsis (n p 15)
MBL !300 ng/mL 6 (40) 17 (18) 3.02 (0.95–9.62) .062 2.99 (0.86–10.33) .084
H-ficolin !12,000 ng/mL 6 (40) 36 (38) 1.07 (0.35–3.27) .900 0.81 (0.24–2.79) .743
L-ficolin !1000 ng/mL 7 (47) 22 (23) 2.86 (0.93–8.79) .066 2.90 (0.77–10.97) .116
MASP-2 !30 ng/mL 5 (33) 39 (41) 0.71 (0.22–2.23) .551 1.44 (0.43–4.85) .558
MASP-3 !3000 ng/mL 9 (60) 34 (36) 2.65 (0.87–8.08) .087 2.04 (0.54–7.69) .293
Early-onset sepsis (n p 13)
MBL !300 ng/mL 6 (46) 17 (18) 3.88 (1.16–13.02) .028c 3.87 (1.05–14.29) .042c
H-ficolin !12,000 ng/mL 6 (46) 36 (38) 1.38 (0.43–4.44) .588 1.00 (0.27–3.68) .998
L-ficolin !1000 ng/mL 5 (38) 22 (23) 2.05 (0.61–6.89) .248 2.31 (0.50–10.64) .284
MASP-2 !30 ng/mL 4 (31) 39 (41) 0.63 (0.18–2.18) .463 1.88 (0.49–7.25) .357
MASP-3 !3000 ng/mL 8 (62) 34 (36) 2.82 (0.86–9.32) .088 2.15 (0.48–9.59) .316
Late-onset sepsis (n p 34)
MBL !300 ng/mL 5 (15) 17 (18) 0.78 (0.26–2.31) .655 0.83 (0.27–2.57) .753
H-ficolin !12,000 ng/mL 21 (62) 36 (38) 2.60 (1.16–5.83) .020c 2.97 (1.21–7.31) .018c
L-ficolin !1000 ng/mL 10 (29) 22 (23) 1.36 (0.57–3.28) .489 1.12 (0.42–3.00) .822
MASP-2 !30 ng/mL 12 (35) 39 (41) 0.77 (0.34–1.74) .528 1.40 (0.59–3.30) .441
MASP-3 !3000 ng/mL 16 (47) 34 (36) 1.57 (0.71–3.47) .266 1.94 (0.75–5.05) .174
NOTE. CI, confidence interval; OR, odds ratio.
a Results of binary logistic regression.
b Including gestational age, chorioamnionitis, mode of delivery, and mechanical ventilation after birth as covariates.
c .P ! .05
d .P ! .01
fants undergoing major surgery during the neonatal period are
exposed to very different risk factors, compared with neonates
not undergoing surgery, such as invasive procedures, open
wounds, and prolonged presence of central catheters. Under
these circumstances, the impact of innate immunity on systemic
infections may be outweighed by the mentioned risk factors.
The association between low MBL concentration and early-
onset sepsis could be the result of MBL consumption in the
course of severe intrauterine infection. Dumestre-Perard et al
[38] observed MBL consumption in patients with gram-neg-
ative sepsis. However, in our study, no association between
chorioamnionitis and MBL was found. We thus believe it more
likely that low MBL cord blood concentration predisposes in-
fants to gram-negative bloodstream infections. Binding of MBL
has been demonstrated in isolates from immunocompromised
children including S. aureus, Listeria monocytogenes, Haemoph-
ilus influenzae, Escherichia coli, and Candida albicans, whereas
only minimal binding was found for GBS and coagulase-neg-
ative staphylococci [14, 15].
Our findings are in line with the results of several studies
involving adults, which indicate that MBL deficiency is asso-
ciated with an increased susceptibility to sepsis [18–21]. Sim-
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Figure 4. Mannan-binding lectin (MBL) concentrations in cord blood in
patients with gram-positive and gram-negative sepsis, compared with con-
trols. P values determined by univariate logistic regression and median
values are shown. The dotted line indicates low MBL concentration (!300
ng/mL).
Table 4. Associations of Low Mannan-Binding Lectin (MBL) and Low H-Ficolin Cord Blood Concentration with Sepsis,
Gram-Positive Sepsis, Gram-Negative Sepsis, Early-Onset Sepsis, and Late-Onset Sepsis in Infants without Surgery
Variable
Frequency, no (%)




(n p 94) OR (95% CI) P OR (95% CI) P
Sepsis (n p 36)
H-ficolin !12,000 ng/mL 22 (61) 36 (38) 2.53 (1.15–5.57) .021c 2.04 (0.88–4.73) .096
Gram-positive sepsis (n p 23)
H-ficolin !12,000 ng/mL 16 (70) 36 (38) 3.68 (1.38–9.82) .009d 3.71 (1.26–10.92) .017c
Gram-negative sepsis (n p 12)
MBL !300 ng/mL 6 (50) 17 (18) 4.53 (1.30–15.77) .018c 4.39 (1.10–17.45) .036c
Early-onset sepsis (n p 13)
MBL !300 ng/mL 6 (46) 17 (18) 3.88 (1.16–13.02) .028c 3.87 (1.05–14.29) .042c
Late-onset sepsis (n p 23)
H-ficolin !12,000 ng/mL 16 (70) 36 (38) 3.68 (1.38–9.82) .009d 3.14 (1.07–9.21) .037c
NOTE. CI, confidence interval; OR, odds ratio.
a Results of binary logistic regression.
b Including gestational age, chorioamnionitis, mode of delivery, and mechanical ventilation after birth as covariates.
c .P ! .05
d .P ! .01
ilarly, 3 recent phenotype-based studies identified MBL defi-
ciency as a risk factor for neonatal sepsis [22–24]. However,
none of these adjusted for precise gestational age and cho-
rioamnionitis. In contrast, 2 studies assessing MBL genotype
reported no association between mutations in the MBL2 gene
and neonatal sepsis [25, 26]. Several problems in these studies
need to be addressed. First, definition of sepsis was variable,
and several studies were based on clinical definitions of infec-
tion. Second, a high proportion of blood cultures yielding co-
agulase-negative staphylococci were included, which could rep-
resent contaminations.
We believe that the present study has several advantages. The
definition of sepsis required the presence of both positive blood
cultures and clinical signs of infection. In the absence of strong
clinical signs of infection, potential contaminations were ex-
cluded. Furthermore, patients were carefully matched with
controls for gestational age, sex, and chorioamnionitis, which
strongly influence the risk of sepsis. Multivariate analyses ad-
justing for several potential confounders and sensitivity analy-
ses excluding patients with postoperative sepsis confirmed the
main results.
Some limitations need to be addressed. Only infants for
whom cord blood was available were included. A selection bi-
as, however, seems unlikely, because cord blood was routinely
taken for determining T. gondii serostatus, a condition which
is highly unlikely to affect lectin pathway concentrations or
sepsis risk. Similar to other studies on MBL and neonatal sepsis
[22–26], sample size is a major limitation. Due to the explor-
atory nature of the analyses, confirmation by future prospec-
tive cohorts is needed.
Because of significant variability in genotype-phenotype cor-
relation and posttranscriptional events, genotype may not be a
sufficient predictor of function in individual patients [25];
therefore, we decided to determine the concentrations of the
proteins. Because data on normal concentrations in the neo-
natal period are lacking, we used cut-offs based on receiver
operating characteristic curve analysis to define low lectin path-
way concentrations.
In conclusion, we report that low MBL cord blood concen-
trations are an important susceptibility factor for gram-negative
sepsis, and low H-ficolin concentrations indicate susceptibility
for gram-positive sepsis. In addition, we demonstrate that ne-
onates, in particular preterm infants, have an immature ex-
pression of the entire lectin pathway, which is likely to con-
tribute to their extraordinary susceptibility to invasive infec-
tions. Our preliminary findings indicate differential pathogen
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specificity within the lectin pathway of complement activation.
Considering that therapeutical studies with MBL replacement
are already underway for children with cancer [39], future pro-
spective studies should include ficolins and MASPs, because
MBL alone may not adequately reflect the impact of the lectin
pathway in susceptibility to infection.
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